Dosing Flexibility
To meet patient needs

2 dosing options and no dose adjustments with many medications

2 Dosing Options1

Recommended Dose is
320 mg Daily

CAN BE COADMINISTERED WITH
GASTRIC ACID REDUCING AGENTS*1

  • Can be taken with or without food. Can be taken with a
    high-fat meal—BRUKINSA drug concentration (AUC) is not affected
  • Advise patients to swallow capsules whole with water—do not open, break, or chew capsules
  • If a dose of BRUKINSA is missed, it should be taken as soon as possible with a return to the normal schedule the following day


BRUKINSA should be taken until disease progression or unacceptable toxicity.

*Includes PPIs, H2RAs, and antacids.


AUC=area under the concentration-time curve; H2RAs=H2-receptor antagonists; PPIs=proton pump inhibitors.

No Dose Adjustments With These Common Medications

Gastric Acid Reducing Agents1

Proton pump inhibitors

Including, but not limited to:

  • Omeprazole
  • Esomeprazole
  • Lansoprazole

H2-receptor antagonists

Including, but not limited to:

  • Famotidine
  • Ranitidine
  • Nizatidine
Anticlotting Medication1,2

Anticoagulants

  • Heparins
  • Direct thrombin inhibitors
  • Factor Xa inhibitors
  • Vitamin K antagonists

Antiplatelets

  • Aspirin
  • P2Y12 inhibitors
  • Phosphodiesterase inhibitors
  • PAR-1 antagonists


BRUKINSA was allowed to be coadministered in clinical trials with antiplatelets and anticoagulants (as long as INR was ≤1.5 and aPTT ≤1.5 x ULN).2-4

Coadministration of BRUKINSA with antiplatelet or anticoagulant medications may increase the risk of hemorrhage. Monitor for signs and symptoms of bleeding.1

Straightforward Dose Modification for ≥Grade 3 Adverse Reactions (ARs)1

Event

  • Grade 3 or higher non-hematological toxicities
  • Grade 3 febrile neutropenia
  • Grade 3 thrombocytopenia with significant bleeding
  • Grade 4 neutropenia (lasting more than 10 consecutive days)
  • Grade 4 thrombocytopenia (lasting more than 10 consecutive days)


Recommended dose modification by occurrence for ≥Grade 3 ARs.1

NO DOSE EXCHANGE REQUIRED
FOR DOSE MODIFICATION

aPTT=activated partial thromboplastin time; INR=International Normalized Ratio;
PAR-1=protease-activated receptor 1; ULN=upper limit of normal.

Powerful and
Sustained Responses
Efficacy
Established
Safety Profile
Safety
Personalized
Patient Support
Patient Support